Clinical Trial Update: Aripiprazole as Augmentation for TRD [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating aripiprazole as augmentation for treatment-resistant depression has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Abilify (aripiprazole) (aripiprazole)

Snippet

Sponsor: State University of New York - Upstate Medical University | Conditions: Depression | Phase 2 | Status: COMPLETED